The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, VISA strains may serve as precursors to the eventual emergence of fully resistant VRSA strains, emphasizing the need for continuous surveillance and novel treatment strategies [216,219,220,221].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [221]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Self-citationWootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Bae, I., Federspiel, J. J., Miró, J. M., Woods, C. W., Park, L., Rybak, M. J., Rude, T. H., Bradley, S., Bukovski, S., de la Maria, C. G., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/606027 · Cited by 122
Research works printed but not linked: 73
- Akins, 2001, Antimicrob. Agents Chemother., 45, 454, 10.1128/AAC.45.2.454-459.2001 · DOI · Paper page
- Bagnoli, 2012, Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials, Front. Cell. Infect. Microbiol., 2, 16, 10.3389/fcimb.2012.00016 · DOI · Paper page
- Boyle-Vavra, 2000, Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates, Antimicrob. Agents Chemother., 44, 272, 10.1128/AAC.44.2.272-277.2000 · DOI
- Boyle-Vavra, 2003, Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance, Antimicrob. Agents Chemother., 47, 2036, 10.1128/AAC.47.6.2036-2039.2003 · DOI
- Boyle-Vavra, 2011, Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure, Antimicrob. Agents Chemother., 55, 2018, 10.1128/AAC.01593-10 · DOI
- Cameron, 2011, The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes, Clin. Infect. Dis., 53, 576, 10.1093/cid/cir473 · DOI
- Cameron, 2012, Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus, J. Infect. Dis., 205, 1677, 10.1093/infdis/jis252 · DOI
- Chambers, 2001, The changing epidemiology of Staphylococcus aureus?, Emerg. Infect. Dis., 7, 178, 10.3201/eid0702.010204 · DOI · Paper page
- Charles, 2004, Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus, Clin. Infect. Dis., 38, 448, 10.1086/381093 · DOI · Paper page
- Cosgrove, 2004, Staphylococcus aureus with reduced susceptibility to vancomycin, Clin. Infect. Dis., 39, 539, 10.1086/422458 · DOI · Paper page
- Cui, 2005, DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 49, 3404, 10.1128/AAC.49.8.3404-3413.2005 · DOI
- Cui, 2003, Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus, J. Clin. Microbiol., 41, 5, 10.1128/JCM.41.1.5-14.2003 · DOI · Paper page
- Cui, 2000, Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50, Antimicrob. Agents Chemother., 44, 2276, 10.1128/AAC.44.9.2276-2285.2000 · DOI · Paper page
- Cui, 2009, Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 1231, 10.1128/AAC.01173-08 · DOI
- de Lassence, 2006, Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit, Clin. Infect. Dis., 42, 170, 10.1086/498898 · DOI
- Delaune, 2012, The WalKR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory response, Infect. Immun., 80, 3438, 10.1128/IAI.00195-12 · DOI · Paper page
- Dubrac, 2008, A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway, Mol. Microbiol., 70, 1307, 10.1111/j.1365-2958.2008.06483.x · DOI · Paper page
- Fukushima, 2011, A role for the essential YycG sensor histidine kinase in sensing cell division, Mol. Microbiol., 79, 503, 10.1111/j.1365-2958.2010.07464.x · DOI
- Gao, 2013, The RpoB H481Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus, J. Infect. Dis., 207, 929, 10.1093/infdis/jis772 · DOI
- Gao, 2010, Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection, PLoS Pathog., 6, e1000944, 10.1371/journal.ppat.1000944 · DOI · Paper page
- Gardete, 2012, Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300, PLoS Pathog., 8, e1002505, 10.1371/journal.ppat.1002505 · DOI · Paper page
- Hafer, 2012, Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 56, 5845, 10.1128/AAC.01139-12 · DOI
- Hanaki, 1998, Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50, J. Antimicrob. Chemother., 42, 199, 10.1093/jac/42.2.199 · DOI · Paper page
- Hiramatsu, 2001, Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance, Lancet Infect. Dis., 1, 147, 10.1016/S1473-3099(01)00091-3 · DOI · Paper page
- Hiramatsu, 1997, Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin, Lancet, 350, 1670, 10.1016/S0140-6736(97)07324-8 · DOI · Paper page
- Hiramatsu, 1997, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J. Antimicrob. Chemother., 40, 135, 10.1093/jac/40.1.135 · DOI · Paper page
- Horne, 2009, Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA, Antimicrob. Agents Chemother., 53, 3447, 10.1128/AAC.01365-08 · DOI
- Howden, 2006, Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia, Antimicrob. Agents Chemother., 50, 3039, 10.1128/AAC.00422-06 · DOI · Paper page
- Howden, 2011, Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR, PLoS Pathog., 7, e1002359, 10.1371/journal.ppat.1002359 · DOI · Paper page
- Howden, 2008, Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia, BMC Microbiol., 8, 39, 10.1186/1471-2180-8-39 · DOI
- Howden, 2008, Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus, Antimicrob. Agents Chemother., 52, 3755, 10.1128/AAC.01613-07 · DOI
- Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin. Infect. Dis., 38, 521, 10.1086/381202 · DOI · Paper page
- Howe, 2004, Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages, Emerg. Infect. Dis., 10, 855, 10.3201/eid1005.030556 · DOI
- Jansen, 2007, Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus, Int. J. Med. Microbiol., 297, 205, 10.1016/j.ijmm.2007.02.002 · DOI · Paper page
- Kaatz, 1990, Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis, J. Infect. Dis., 162, 103, 10.1093/infdis/162.1.103 · DOI · Paper page
- Katayama, 2000, A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 44, 1549, 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
- Katayama, 2009, Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem, Antimicrob. Agents Chemother., 53, 3190, 10.1128/AAC.00834-08 · DOI
- Kelley, 2011, Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure, J. Antimicrob. Chemother., 66, 1057, 10.1093/jac/dkr066 · DOI
- Koehl, 2004, Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 48, 3749, 10.1128/AAC.48.10.3749-3757.2004 · DOI
- Lowy, 1998, Staphylococcus aureus infections, N. Engl. J. Med., 339, 520, 10.1056/NEJM199808203390806 · DOI · Paper page
- Lowy, 2003, Antimicrobial resistance: the example of Staphylococcus aureus, J. Clin. Invest., 111, 1265, 10.1172/JCI200318535 · doi:10.1172/jci200318535 · Paper page
- Majcherczyk, 2008, Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis, Microb. Pathog., 45, 408, 10.1016/j.micpath.2008.09.003 · DOI
- Manquat, 1992, Failure of teicoplanin treatment associated with an increase in MIC during therapy of Staphylococcus aureus septicaemia, J. Antimicrob. Chemother., 29, 731, 10.1093/jac/29.6.731 · DOI
- Maor, 2009, Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia, J. Infect. Dis., 199, 619, 10.1086/596629 · DOI · Paper page
- Marco, 2008, Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 52, 2538, 10.1128/AAC.00510-07 · DOI
- Matsuo, 2011, Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3, Antimicrob. Agents Chemother., 55, 4188, 10.1128/AAC.00398-11 · DOI
- McAleese, 2006, Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin, J. Bacteriol., 188, 1120, 10.1128/JB.188.3.1120-1133.2006 · DOI · Paper page
- McCallum, 2006, In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance, Antimicrob. Agents Chemother., 50, 2352, 10.1128/AAC.00073-06 · DOI
- Moise, 2009, Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions, Lancet Infect. Dis., 9, 617, 10.1016/S1473-3099(09)70200-2 · DOI
- Musta, 2009, Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11years, J. Clin. Microbiol., 47, 1640, 10.1128/JCM.02135-08 · DOI
- Mwangi, 2007, Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing, Proc. Natl. Acad. Sci. USA, 104, 9451, 10.1073/pnas.0609839104 · DOI · Paper page
- Neoh, 2008, Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance, Antimicrob. Agents Chemother., 52, 45, 10.1128/AAC.00534-07 · DOI
- Park, 2012, Downregulation of RNAIII in vancomycin-intermediate Staphylococcus aureus strains regardless of the presence of agr mutation, J. Med. Microbiol., 61, 345, 10.1099/jmm.0.035204-0 · doi:10.1099/jmm.0.035204-0
- Passalacqua, 2012, A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin, Antimicrob. Agents Chemother., 56, 5212, 10.1128/AAC.05770-11 · DOI
- Peleg, 2009, Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection, J. Infect. Dis., 199, 532, 10.1086/596511 · DOI · Paper page
- Pereira, 2007, Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 51, 3627, 10.1128/AAC.00431-07 · DOI
- Perichon, 2009, VanA-type vancomycin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 4580, 10.1128/AAC.00346-09 · DOI · Paper page
- Pfeltz, 2000, Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds, Antimicrob. Agents Chemother., 44, 294, 10.1128/AAC.44.2.294-303.2000 · DOI
- Pillai, 2009, Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus, Clin. Infect. Dis., 49, 1169, 10.1086/605636 · DOI
- Rammelkamp, 1942, Resistance of Staphylococcus aureus to the action of penicillin, Proc. Royal Soc. Exper. Biol. Med., 51, 386, 10.3181/00379727-51-13986 · DOI · Paper page
- Renzoni, 2011, Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus, PLoS One, 6, e21577, 10.1371/journal.pone.0021577 · DOI
- Robert, 2006, Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20year study in a large French teaching hospital, 1983–2002, J. Antimicrob. Chemother., 57, 506, 10.1093/jac/dki486 · DOI
- Rybak, 2005, Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin, Diagn. Microbiol. Infect. Dis., 51, 119, 10.1016/j.diagmicrobio.2004.09.005 · DOI
- Scherl, 2006, Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers, BMC Genomics, 7, 296, 10.1186/1471-2164-7-296 · DOI
- Shoji, 2011, WalK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus, Antimicrob. Agents Chemother., 55, 3870, 10.1128/AAC.01563-10 · DOI
- Sieradzki, 2003, Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus, J. Bacteriol., 185, 7103, 10.1128/JB.185.24.7103-7110.2003 · DOI · Paper page
- Smith, 1999, Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus working group, N. Engl. J. Med., 340, 493, 10.1056/NEJM199902183400701 · DOI · Paper page
- Tenover, 2007, The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus, Clin. Infect. Dis., 44, 1208, 10.1086/513203 · DOI · Paper page
- Tenover, 2009, Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy, Int. J. Antimicrob. Agents, 33, 564, 10.1016/j.ijantimicag.2008.12.010 · DOI
- van Hal, 2011, Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections, PLoS One, 6, e21217, 10.1371/journal.pone.0021217 · DOI
- van Hal, 2011, Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates, Antimicrob. Agents Chemother., 55, 405, 10.1128/AAC.01133-10 · DOI · Paper page
- Watanabe, 2011, Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus, J. Clin. Microbiol., 49, 2680, 10.1128/JCM.02144-10 · DOI · Paper page
- Yamakawa, 2012, Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study, J. Infect. Chemother., 18, 406, 10.1007/s10156-011-0330-2 · DOI
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Foster, T. J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux007 · Cited by 845
Mechanisms of vancomycin resistance in Staphylococcus aureus
Gardete, S., & Tomasz, A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68834 · Cited by 565
Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens
Baker, S., Thomson, N., Weill, F.-X., & Holt, K. E. (2018) · Science · doi:10.1126/science.aar3777 · Cited by 401
Glycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Metadata
- Authors
- Howden, B. P., Peleg, A. Y., & Stinear, T. P.
- Venue
- Infection, Genetics and Evolution
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 21
- Pages
- 575-582
- ISSN
- 1567-1348
- Cited by
- 128
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. https://app.cochat.ai/papers/10.1016/j.meegid.2013.03.047
- The paper
- Howden, B. P., Peleg, A. Y., & Stinear, T. P. (2014). The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infection, Genetics and Evolution. https://doi.org/10.1016/j.meegid.2013.03.047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.